Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

Q3 2012.

INTUNIV - ADHD

The strong growth in INTUNIV product sales (up 17%) in Q3 2013 was driven by a combination of increased US prescription demand (up 8%) and the effect of price increases taken since Q3 2012. The benefit of these increases was partially offset by higher sales deductions in Q3 2013 as compared to Q3 2012.

PENTASA - Ulcerative Colitis

PENTASA product sales (up 5%) benefited from price increases taken since Q3 2012 partially offset by higher sales deductions in Q3 2013 as compared to Q3 2012.

FIRAZYR - Hereditary Angioedema

FIRAZYR product sales growth (up 107%) was primarily driven by the US market, where the number of new patients on therapy continues to grow strongly.

DERMAGRAFT - Diabetic Foot Ulcers

DERMAGRAFT product sales were down 29% compared to Q3 2012.

2.    Royalties

Year on year growth Royalties to Product Shire $M Royalties CER FOSRENOL(R) 1.00 13.8 -1% -2% 3TC(R) and ZEFFIX(R) 1.00 10.1 -5% -5% ADDERALL XR 1.00 6.2 -45% -45% Other 1.00 7.5 +25% +23% Total 1.00 37.6 -10% -10%

3.    Financial details

Cost of product sales

% of % of product product Q3 2013 sales Q3 2012 sales $M $M Cost of product sales (US GAAP) 197.1 16% 167.9 16% Depreciation (11.0) (9.4) Cost of product sales (Non GAAP) 186.1 16% 158.5 15%

Cost of product sales as a percentage of product sales remained broadly constant in Q3 2013 as compared to Q3 2012.

Research and Development ("R&D")

% of % of product product Q3 2013 sales Q3 2012 sales $M $M R&D (US GAAP) 229.1 19% 224.7 21% Depreciation (6.3) (5.5) R&D (Non GAAP) 222.8 19% 219.2 21%

Non GAAP R&D increased by $3.6 million, or 2%[1], due to the continued investment in our R&D pipeline, primarily on non-ADHD programs for LDX, on SHP602 (formerly known as SPD602) for iron o
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is pleased ... elected Chairman of the Board, to succeed Donald Fresne ... but will continue as a member of the Board.  In ... added to the company over almost twenty years, the Board ... Board of Directors has established a Search Committee to find ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... significant financial obligation and improves balance sheetROCKVILLE, Md., April ... a leader in the development of novel vaccines, today ... with holders of $17 million of the total $22 ... carried a coupon rate of 4.75% payable semi-annually and ...
... to Identify a Population with Blood-Based Biomarkers for ... Optherion, Inc., a company developing novel molecular ... Macular Degeneration (AMD) and other chronic diseases involving ... will be reporting data from its diagnostics development ...
... MSEDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), ... today announced that Mr. Kevin Giese, President and CEO, will ... development of a world class technology sector" as part of ... WHEN: Monday May 4th at ...
Cached Biology Technology:Novavax Announces Early Retirement of $17 Million of Convertible Debt 2Novavax Announces Early Retirement of $17 Million of Convertible Debt 3BioMS Medical to present at Alberta Economic Forum in Geneva 2
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... may have been right all along ?a siesta after a ... The University of Manchester have for the first time uncovered ... turned off after we eat. , The findings ?published in ... obesity and eating disorders as well as understanding levels of ...
... of Medicine and Public Health has discovered a new part ... vessels, or angiogenesis. , The finding may help halt ... author on the study, a professor of pharmacology and member ... , The research, published in the Journal of Cell Biology ...
... an animal's immune response to the 1918 influenza virus ... supported scientists in an article appearing online today in ... that the 1918 virus triggers a hyperactive immune response ... Furthermore, their results suggest that it is the ...
Cached Biology News:Why we could all do with a siesta 2New angiogenesis finding may help fight cancer growth 2New angiogenesis finding may help fight cancer growth 3New angiogenesis finding may help fight cancer growth 4Mouse study reveals new clues about virulence of 1918 influenza virus 2Mouse study reveals new clues about virulence of 1918 influenza virus 3
... Microarrays designed for DNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... synthesized on-chip and LC Sciences can provide ... are available as part of our comprehensive ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... sequence is from the C-terminal end of the mouse retinoic acid receptor ... 429 to 448 of RAR*. The sequence of PEP-005 is (amino ... - P - S - S - V - E - N ... - P - L - L - Q (The N-terminal cysteine ...
... the next step in the evolution of ... system that delivers labware to multiple laboratory ... times the throughput of ordinary microplate robots. ... variety of configurations to meet any labs ...
Biology Products: